- Home
- Blogs
New EU guidance on agreements sharing health data
Author
Browse this blog post
Related news and insights
Publications: 16 November 2023
ECJ’s “gun jumping” ruling reminds merging parties of the importance of EU merger control compliance
Publications: 26 October 2023
Third annual report on EU foreign investment reveals a significant increase in formal screenings
Blog Post: 23 October 2023
Blog Post: 12 October 2023
Updated transparency rules for EU clinical trials - the end of the deferral mechanism
The long-awaited drafts contain a number of amendments and clarifications which aim to adjust the current ten-year old rules to take into account recent societal and economic developments such as the green transition and digitalisation. The drafts include new rules on the assessment of, in particular, agreements pursuing sustainability objectives, joint purchasing agreements, bidding consortia and data sharing.
Of particular interest to pharmaceutical companies is the proposed guidance on data sharing. The EC recognises that while data sharing may generate certain efficiency gains, in some circumstances it may lead to anti-competitive foreclosure. This may happen, for example, when the data shared is of strategic importance, it represents a large part of the market and third parties’ access is prevented. The draft guidelines set out the factors that companies should take into account when assessing whether a data sharing initiative could breach EU antitrust rules.
The draft also sheds some light on the preventive measures that can be used to reduce potential antitrust concerns. The EC makes it clear that data pool participants should only have access to their own information and the final and aggregated information of other participants.
Interested parties can submit their comments until 26 April 2022. The new rules will come into force on 1 January 2023. For more information, please see our alert.